Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
| العنوان: | Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial |
|---|---|
| المؤلفون: | Halim Issever, Ahmet Serhan Dagistanli, Mustafa Erelel, Alpay Medetalibeyoglu, Nur Sena Basarir, Hilal Balkanci, Tufan Tükek, Ayca Yildiz-Pekoz, Aybige Erturk, Mustafa Oral Öncül, Merve Sinem Oguz, Mert Kaskal, Aygun Qarayeva, Ahmet Araman, Ali Yağız Üresin, Gokben Sahin, Ozlem Akbal-Dagistan, Meltem Culha |
| المساهمون: | İstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, Erturk, Aybige, Erelel, Mustafa, Kaskal, Mert, Akbal-Dagistan, Ozlem, Issever, Halim, Dagistanli, Ahmet Serhan, Balkanci, Hilal, Oguz, Merve Sinem, Qarayeva, Aygun, Culha, Meltem, Basarir, Nur Sena, Sahin, Gokben, Uresin, Ali Yagiz, Araman, Ahmet Ogul, Medetalibeyoglu, Alpay, Tukek, Tufan, Oncul, Mustafa Oral, Yildiz-Pekoz, Ayca |
| المصدر: | Pharmaceutics Volume 13 Issue 11 Pharmaceutics, Vol 13, Iss 1768, p 1768 (2021) |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Coronavirus disease 2019 (COVID-19), medicine.drug_class, pulmonary, Pharmaceutical Science, Low molecular weight heparin, Article, Hypoxemia, Pharmacy and materia medica, BINDING, medicine, Soft-mist İnhaler, BERLIN DEFINITION, low-molecular-weight heparin, soft-mist inhaler, RECEPTOR, business.industry, Inhaler, MORTALITY, anti-coagulant, Anti-coagulan, COVID-19, Heparin, Clinical trial, RS1-441, Anesthesia, Breathing, VIRUS, ARDS, medicine.symptom, business, Soft mist inhaler, medicine.drug |
| الوصف: | In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group” 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1999-4923 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb341af61ca44d3fcdde579b17139693 http://europepmc.org/articles/PMC8618458 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....eb341af61ca44d3fcdde579b17139693 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19994923 |
|---|